These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 6141708)

  • 1. Chairman's introduction: role of the pallidum and its transmitters in the therapy of parkinsonian rigidity and akinesia.
    Hassler RG
    Adv Neurol; 1984; 40():1-14. PubMed ID: 6141708
    [No Abstract]   [Full Text] [Related]  

  • 2. Three types of akinesia in the progressive course of Parkinson's disease.
    Narabayashi H
    Adv Neurol; 1993; 60():18-24. PubMed ID: 8093577
    [No Abstract]   [Full Text] [Related]  

  • 3. The subthalamic nucleus: a possible target for stereotaxic surgery in Parkinson's disease.
    Guridi J; Luquin MR; Herrero MT; Obeso JA
    Mov Disord; 1993 Oct; 8(4):421-9. PubMed ID: 8232351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transplantation and surgical treatment of parkinsonian syndromes.
    Widner H; Rehncrona S
    Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):344-9. PubMed ID: 8507904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms compensating for dopamine loss in early Parkinson disease.
    Brotchie J; Fitzer-Attas C
    Neurology; 2009 Feb; 72(7 Suppl):S32-8. PubMed ID: 19221312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opposite motor effects of pallidal stimulation in Parkinson's disease.
    Krack P; Pollak P; Limousin P; Hoffmann D; Benazzouz A; Le Bas JF; Koudsie A; Benabid AL
    Ann Neurol; 1998 Feb; 43(2):180-92. PubMed ID: 9485059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of neostriatal and mesostriatal or mesolimbic dopaminergic fibres in Parkinson's disease with and without dementia: prospects, concepts and facts.
    Cools AR
    Yakubutsu Seishin Kodo; 1990 Mar; 10(1):15-34. PubMed ID: 2220127
    [No Abstract]   [Full Text] [Related]  

  • 8. Movement disorders stereotactic surgery for Parkinson's disease.
    Iacono RP; Lonser R; Morenski JD
    Mov Disord; 1994 Jul; 9(4):470-2. PubMed ID: 7848465
    [No Abstract]   [Full Text] [Related]  

  • 9. Pathophysiology of motor fluctuations in Parkinson's disease.
    Widnell K
    Mov Disord; 2005; 20 Suppl 11():S17-22. PubMed ID: 15822108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deep brain stimulation in Parkinson's disease: opposite effects of stimulation in the pallidum.
    Bejjani BP; Damier P; Arnulf I; Papadopoulos S; Bonnet AM; Vidailhet M; Agid Y; Pidoux B; Cornu P; Dormont D; Marsault C
    Mov Disord; 1998 Nov; 13(6):969-70. PubMed ID: 9827624
    [No Abstract]   [Full Text] [Related]  

  • 11. Physiology of the normal and dopamine-depleted basal ganglia: insights into levodopa pharmacotherapy.
    Grace AA
    Mov Disord; 2008; 23 Suppl 3():S560-9. PubMed ID: 18781673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parkinson's disease and the adaptive capacity of the nigrostriatal dopamine system: possible neurochemical mechanisms.
    Hornykiewicz O
    Adv Neurol; 1993; 60():140-7. PubMed ID: 8420131
    [No Abstract]   [Full Text] [Related]  

  • 13. Parkinson's disease.
    DeLong M
    Neurobiol Dis; 2000 Oct; 7(5):559-60. PubMed ID: 11042077
    [No Abstract]   [Full Text] [Related]  

  • 14. The role of the pallidum in Parkinson's disease gait. Lessons from pallidal stimulation.
    Damier P; Houeto JL; Bejjani BP; Arnulf I; Bonnet AM; Miloudy M; Agid Y
    Adv Neurol; 2001; 87():283-8. PubMed ID: 11347233
    [No Abstract]   [Full Text] [Related]  

  • 15. Dynamic aspects of the striatothalamic connection studied in cases with movement disorder.
    Ohye C
    Adv Neurol; 1993; 60():78-83. PubMed ID: 8420220
    [No Abstract]   [Full Text] [Related]  

  • 16. Electrophysiological and clinical desensitization to apomorphine administration in parkinsonian patients undergoing stereotaxic neurosurgery.
    Stefani A; Mazzone P; Bassi A; Bernardi G; Altibrandi MG; Peppe A; Pierantozzi M; Stanzione P
    Exp Neurol; 1999 Mar; 156(1):209-13. PubMed ID: 10192792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical aspects of Parkinson's disease.
    Nagatsu T
    Adv Neurol; 1993; 60():165-74. PubMed ID: 8093575
    [No Abstract]   [Full Text] [Related]  

  • 18. Thirty years of dopamine research.
    Carlsson A
    Adv Neurol; 1993; 60():1-10. PubMed ID: 8093570
    [No Abstract]   [Full Text] [Related]  

  • 19. Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease.
    Obeso JA; Rodríguez-Oroz MC; Benitez-Temino B; Blesa FJ; Guridi J; Marin C; Rodriguez M
    Mov Disord; 2008; 23 Suppl 3():S548-59. PubMed ID: 18781672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms.
    Bravi D; Mouradian MM; Roberts JW; Davis TL; Sohn YH; Chase TN
    Ann Neurol; 1994 Jul; 36(1):27-31. PubMed ID: 8024257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.